Risedronate 35/150 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Osteoporosis

• Alendronate
• Ibandronate
• Raloxifene

About Risedronate 35/150 mg tabs

Risedronate 35/150 mg tablets are a cornerstone medication for managing and preventing bone loss, primarily for individuals facing osteoporosis. At TheDrugClub, we believe essential health should be accessible and affordable. Our members can significantly reduce their medication expenses, often accessing risedronate for a $0 co-pay, complete with convenient home delivery.

What Risedronate Treats

Risedronate, available in strengths like 35 mg (typically taken weekly) and 150 mg (typically taken monthly), is a widely prescribed medication primarily used to strengthen bones. Its main indications include the treatment and prevention of osteoporosis in postmenopausal women, osteoporosis in men, and glucocorticoid-induced osteoporosis (bone loss caused by steroid medications). It's also used to treat Paget's disease of bone, a chronic condition that results in enlarged and misshapen bones. By bolstering bone density and reducing bone turnover, risedronate plays a crucial role in decreasing the risk of debilitating fractures, such as those of the hip and spine, which are common complications of osteoporosis.

How Risedronate Works

Risedronate belongs to a class of drugs known as bisphosphonates. These medications work by slowing down the natural process of bone breakdown. Our bones are constantly undergoing a remodeling process, where old bone tissue is removed by cells called osteoclasts, and new bone tissue is formed by osteoblasts. In conditions like osteoporosis, the rate of bone breakdown outpaces bone formation, leading to weaker, more porous bones.

When you take risedronate, it attaches to the surfaces of your bones and is then absorbed by the osteoclasts. Once inside these cells, rised

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Risedronate 35/150 mg tabs is approved for (FDA label)

Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget’s disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Source: Read the full FDA label on DailyMed. Label effective date: March 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Risedronate 35/150 mg tabs (FDA label)

5 mg: yellow, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7390” on the other side. 30 mg: white, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7391” on the other side. 35 mg: orange, round, standard convex, film-coated, debossed with “TEVA” on one side of the tablet and “7389” on the other side. Tablets: 5 mg, 30 mg, and 35 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Risedronate 35/150 mg tabs (FDA label)

The following clinically significant adverse drug reactions are described elsewhere in the labeling: Drug Products with the Same Active Ingredient [see Warnings and Precautions ( 5.1 )] Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.2 )] Mineral Metabolism [see Warnings and Precautions ( 5.3 )] Jaw Osteonecrosis [see Warnings and Precautions ( 5.4 )] Musculoskeletal Pain [see Warnings and Precautions ( 5.5 )] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions ( 5.6 )] Renal Impairment [see Warnings and Precautions ( 5.7 )] Glucocorticoid-Induced Osteoporosis [see Warnings and Precautions ( 5.8 )] Laboratory Test Interactions [see Warnings and Precautions ( 5.9 )] Most common adverse reactions reported in greater than 10% of patients treated with risedronate and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia ( 6.1 ) Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis), and eye inflammation (iritis, uveitis) have been reported rarely ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Risedronate 35/150 mg tabs (FDA label)

Risedronate sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see Warnings and Precautions ( 5.1 )] Inability to stand or sit upright for at least 30 minutes [see Dosage and Administration ( 2 ), Warnings and Precautions ( 5.1 )] Hypocalcemia [see Warnings and Precautions ( 5.2 )] Known hypersensitivity to risedronate sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported [see Adverse Reactions ( 6.2 )] Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 , 5.1) Inability to stand or sit upright for at least 30 minutes ( 4 , 5.1) Hypocalcemia ( 4 , 5.3 ) Known hypersensitivity to any component of this product ( 4 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Risedronate 35/150 mg tabs (FDA label)

Products Containing Same Active Ingredient: Patients receiving Atelvia should not be treated with risedronate sodium ( 5.1 ) Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur ( 5.2 ) Hypocalcemia may worsen and must be corrected prior to use ( 5.3 ) Osteonecrosis of the Jaw has been reported ( 5.4 ) Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop ( 5.5 , 6.2 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Risedronate 35/150 mg tabs (FDA label)

No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of risedronate ( 7.1 ) 7.1 Calcium Supplements/Antacids Co-administration of risedronate and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of risedronate. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with risedronate sodium tablets 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone.

Source: FDA prescribing information (DailyMed). Set ID: dddcd321-4d2e-4643-bf3c-7b752b33ba39. SPL document ID: 641c2a59-be2b-4246-8990-b7bf563012be. Label effective date: March 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.